BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 12.89B |
| Revenue (ttm) | 502.08M |
| Net Income (ttm) | -724.93M |
| Shares Out | 193.86M |
| EPS (ttm) | -3.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,261,430 |
| Open | 66.42 |
| Previous Close | 67.61 |
| Day's Range | 65.46 - 68.47 |
| 52-Week Range | 28.33 - 84.94 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 82.26 (+23.74%) |
| Earnings Date | Feb 24, 2026 |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $82.26, which is an increase of 23.74% from the latest price.
News
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio to Participate in March Investor Conferences
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
Allspring Growth Fund Q4 2025 Fund Performers And Detractors
Carpenter Technology Corp. multiple long-term contracts were repriced favorably as airlines keep aging fleets in service longer driving higher maintenance needs. Natera, Inc. doubled the number of onc...
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
I initiate BridgeBio with a Neutral rating and a $74 target price, reflecting balanced opportunity and risk. ATTR-CM launch of Attruby reduces binary risk, but commercial sustainability and pricing du...
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the fir...
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, an...
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Has More Room To Run
BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 and infigratinib. I expect 2026 to be another strong year with Attruby U.S. n...
BridgeBio to Participate in December Investor Conferences
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes
BridgeBio has surged 90% since April 2025, driven by major clinical trial successes and robust commercial execution. BBIO's BBP-418 and Encaleret trials both exceeded expectations, each targeting bill...
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
BridgeBio Pharma, Inc. ( BBIO) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wad...
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared t...
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enfor...
BridgeBio to Participate in November Investor Conferences
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
